Company: CYTK
Filing Date: 2025-03-31
Form Type: PRE 14A
Source: 0001140361-25-011212
Chunk: 91

Company: CYTOKINETICS INC
Filing Date: 2025-03-31
Form: PRE 14A
Chunk 91
---
    Adjustment 
    $(427,101) |
|:-----|:----|----------------:|:----|---------------------:|:----|-------------------:|:----|---------------------:|:----|:-----------------------|:----|--------------:|
| 2023 |     |      $4,386,915 |     |           $1,876,679 |     |           $201,402 |     |           $(689,660) |     | $—                     |     |    $5,775,336 |
| 2022 |     |      $1,698,148 |     |           $(451,058) |     |           $211,375 |     |           $(182,059) |     | $(475,330)             |     |      $801,075 |
| 2021 |     |      $3,875,707 |     |           $1,580,194 |     |           $140,931 |     |             $211,963 |     | $—                     |     |    $5,808,795 |
| 2020 |     |      $1,477,028 |     |             $679,612 |     |           $172,143 |     |             $330,603 |     | $—                     |     |    $2,659,384 |

| (5) | Cumulative TSR is calculated by the difference between the Company’s share price at the end and the beginning of the measurement period by the Company’s share price at the beginning of the measurement period. “Measurement period” is defined as: for 2020, the one-year period from market close December 31, 2019 through December 31, 2020; for 2021, the two-year period from market close on December 31, 2019 through December 31, 2021; for 2022, the three-year period from market close December 31, 2019 through December 31, 2022; for 2023, the four-year period from market close December 31, 2019 through December 31, 2023; and for 2024, the five-year period from market close December 31, 2019 through December 31, 2024. |

| (6) | Represents the Nasdaq Biotechnology Index. |

| (7) | Wedo not have a Company Selected Financial Measureas described in Item 402(v)(